Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + perifosine
- Development stage
- Phase 3
- Lead developer
- Akebia Therapeutics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Capecitabine + perifosine is an investigational oral combination therapy for cancer, primarily studied in metastatic colorectal cancer (mCRC). Capecitabine is a prodrug of 5-fluorouracil (5-FU), an antimetabolite that inhibits DNA synthesis by interfering with thymidylate synthase. Perifosine is a synthetic alkylphospholipid that modulates multiple signal transduction pathways, notably inhibiting Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, as well as affecting MAPK and JNK pathways. Perifosine also inhibits NF-κB and blocks localization of Akt to the cell membrane, promoting apoptosis and potentially overcoming resistance to chemotherapy. The combination has demonstrated synergistic effects in preclinical and clinical studies, showing improved time to progression and overall survival compared to capecitabine alone in patients with refractory mCRC[1][2][4][5][6].
- Other names
- P-CAP
02
Targets
TS (Thymidylate synthase)NF-κBAKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on capecitabine + perifosine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + perifosine.